New York, United States – Zoetis Inc, a leading animal health company, recently participated in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, with CEO Kristin Peck and CFO Wetteny Joseph sharing insights about the company’s performance and future plans. The conference provided a platform for discussing Zoetis’ recent accomplishments, including the launch of innovative products like Librela in the U.S. and the company’s continued growth in the companion animal portfolio.

During the conference, Kristin Peck highlighted Zoetis’ focus on innovation and its ability to outperform competitors through product development and strategic execution. The company’s disciplined approach to capital allocation was also emphasized, with a recent divestiture of its MFA business to reinvest in high-growth areas. With a strong emphasis on driving operational growth and maintaining long-term guidance, Zoetis aims to sustain its momentum in the coming years.

Wetteny Joseph provided insights into Zoetis’ operational growth, particularly in companion animal and livestock segments. The company’s success in growing its companion animal business, especially with products like Apoquel and Trio, reflects its commitment to meeting market demands and driving innovation. Additionally, the discussion touched upon the company’s pricing strategies and the potential for future growth through expansion into new markets and product categories.

The conversation also delved into the performance of key products like Librela and Solensia, highlighting their positive reception in the market and future growth prospects. The strategic focus on compliance, product innovation, and market expansion underscores Zoetis’ commitment to delivering value to customers and driving sustainable growth in the animal health industry.

Looking ahead, Zoetis remains dedicated to leveraging its strong market position, innovative product portfolio, and strategic partnerships to drive growth and profitability. With a focus on expanding into new therapeutic areas like renal CKD and cardiovascular health, the company is poised for continued success in the evolving animal health landscape.